Frontiers in Oncology

New Publication: Clinical Overview of MDM2/X-Targeted Therapies

Posted on Updated on

Figure1

Great news, we have a new Mini-Review published in Frontiers Oncology entitled “Clinical Overview of MDM2/X-Targeted Therapies“, which is apart of the Research Topic Human tumor-derived p53 mutants: a growing family of oncoproteins

Here is a little snippet from the Abstract to wet your appetite!

MDM2 and MDMX are the primary negative regulators of p53, which under normal conditions maintain low intracellular levels of p53 by targeting it to the proteasome for rapid degradation and inhibiting its transcriptional activity. Both MDM2 and MDMX function as powerful oncogenes and are commonly over-expressed in some cancers, including sarcoma (~20%) and breast cancer (~15%).

In this overview, we will review the current MDM2- and MDMX-targeted therapies in development, focusing particularly on compounds that have entered into early phase clinical trials. We will highlight the challenges pertaining to predictive biomarkers for and toxicities associated with these compounds, as well as identify potential combinatorial strategies to enhance its anti-cancer efficacy.

The article is Open Access, which means its free for everyone and anyone to read and download!

You can view and download it directly here [Link]

Advertisements

Our Latest Review Article “Stressing Mitosis to Death” is now online !

Posted on Updated on

Great news, our latest review article “Stressing Mitosis to Death” has been accepted for publication by Frontiers in Oncology. You can access the provisional pre-press version here.

The review is about how common stresses affect mitosis, and the impact these stresses can have on the blockbuster mitotic chemotherapy drug Taxol (paclitaxel)

Finally here is one of the beautiful figures drawn by our own Sam Rogers for the Review!  Hope you enjoy the read !

 

Fig. v4